Syngene International shares surge 12%, biggest 1-day gain in 6 years; what drove the rally despite a Q2 profit drop?
Syngene International moved higher in a quarterly results development.
· LiveMint Markets
Syngene International shares surged 12% after the company reported a sequential turnaround in September-quarter profit, rising to ₹32.2 crore from a June-quarter loss.
The analysis
Syngene International reported ₹32.2 crore, with movement of 12% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is +12.2% on the day at ₹410.85, and has returned +0.4% over three months. It sits 38% below its 52-week high, which means a good deal of bad news was already in the price. The pharma & healthcare sector has moved -1.0% over the same period, so Syngene International is running 1.4 points ahead of its peers.
For Syngene International, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- In focus: Syngene International (SYNGENE), in Pharma & Healthcare.
- Over three months: Syngene International +0.4% against Pharma & Healthcare -1.0% (1.4 points ahead).
- At least 25% below the 52-week high: Syngene International (38%).
- Trading well above normal today: Syngene International at 13.9 times its 20-day average volume.
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Syngene InternationalSYNGENE · Pharma & Healthcare | ₹410.85 | +12.2% | +9.3% | +0.4% | -38.1% | 13.9× | — |
Pharma & Healthcare
1M -3.1% · 3M -1.0%
Syngene International
Prices as of 28 Oct 2026, 16:11 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore, revenue slips 2%
Cipla’s US recovery, biosimilar pipeline key to future growth prospects
OneSource Specialty Pharma shares jump 14% after Q2 results; recover 50% from recent lows
Acutaas Chemicals rallies 13%; hits record high on strong Q2 results
Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore